Mechanism of Resistance to Platinum Anticancer Drugs – University of Copenhagen

Mechanism of Resistance to Platinum Anticancer Drugs

 

More than 50 percent of all cancer patients are treated with chemotherapy in the form of platinum drugs. However, development of resistance limits the effectiveness of treatment and the mechanism for resistance remains poorly defined.

The aim of the project is therefore to determine the mechanism of resistance to platinum drugs, thereby ideally improving the outcome of chemotherapy.
Platinum drugs cause cancer cell death by binding to DNA in the cell nuclei.
Our hypothesis is that resistant cells bind platinum drugs to cytosolic proteins, which either transport the drug out of the cell or hamper its entry into the cell nucleus.
We therefore work on elucidating the mechanism of resistance by identifying platinum binding proteins in different compartments of the cell, i.e. cytosol, mitochondria, nuclei etc. This should ideally reveal differences between resistant and sensitive cells regarding platinum binding proteins and compartmental location of platinum drug.

The project is a collaboration between Metallomics Lab (SUND) and the Taurin Group (SCIENCE) and combines analytical chemistry and cell biology.